Enanta Pharmaceuticals’ (ENTA) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report released on Friday morning, Benzinga reports. They currently have a $22.00 target price on the biotechnology company’s stock.

Several other analysts have also recently issued reports on ENTA. HC Wainwright reissued a buy rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, August 6th. Evercore ISI raised shares of Enanta Pharmaceuticals to a strong-buy rating in a research note on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an underweight rating for the company in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of Hold and a consensus target price of $19.00.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $10.05 on Friday. The business has a 50 day moving average price of $12.79 and a 200 day moving average price of $13.48. The company has a market capitalization of $212.85 million, a P/E ratio of -1.64 and a beta of 0.59. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.36. The company had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. Enanta Pharmaceuticals’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.27) EPS. As a group, research analysts expect that Enanta Pharmaceuticals will post -5.3 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Scott T. Rottinghaus sold 4,299 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now directly owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Scott T. Rottinghaus sold 4,299 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now directly owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott T. Rottinghaus sold 5,375 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares of the company’s stock, valued at $370,926.36. The disclosure for this sale can be found here. 13.64% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farallon Capital Management LLC raised its stake in shares of Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Enanta Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after purchasing an additional 10,952 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 8,645 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after purchasing an additional 18,003 shares in the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.